CoChat

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

Open access
Annunziata, Christina M., Hernandez, Lidia, Davis, R. Eric, Zingone, Adriana, Lamy, Laurence, Lam, Lloyd T., Hurt, Elaine M., Shaffer, Arthur L., Kuehl, W. Michael, Staudt, Louis M. · 2011 · Blood
Cited by 75

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Modulating aberrant transcription of oncogenes is a relatively unexplored opportunity in cancer therapeutics. In approximately 10% of multiple myelomas, the initiating oncogenic event is translocation of musculoaponeurotic fibrosarcoma oncogene homolog (MAF), a transcriptional activator of key target genes, including cyclinD2. Our prior work showed that MAF is up-regulated in an additional 30% of multiple myeloma cases. The present study describes a common mechanism inducing MAF transcription in both instances. The second mode of MAF transcription occurred in myelomas with multiple myeloma SET domain (MMSET) translocation. MMSET knockdown decreased MAF transcription and cell viability. A small-molecule screen found an inhibitor of mitogen-activated protein kinase kinase (MEK), which activates extracellular signal-regulated kinase (ERK)-MAP kinases, reduced MAF mRNA in cells representing MMSET or MAF subgroups. ERK activates transcription of FOS, part of the AP-1 transcription factor. By chromatin immunoprecipitation, FOS bound the MAF promoter, and MEK inhibition decreased this interaction. MEK inhibition selectively induced apoptosis in MAF-expressing myelomas, and FOS inactivation was similarly toxic. Reexpression of MAF rescued cells from death induced by MMSET depletion, MEK inhibition, or FOS inactivation. The data presented herein demonstrate that the MEK-ERK pathway regulates MAF transcription, providing molecular rationale for clinical evaluation of MEK inhibitors in MAF-expressing myeloma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-04-278788

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 4 references

Cited by

See all 75

Metadata

Authors
Annunziata, C. M., Hernandez, L., Davis, R. E., Zingone, A., Lamy, L., Lam, L. T., Hurt, E. M., Shaffer, A. L., Kuehl, W. M., & Staudt, L. M.
Venue
Blood
Published
2011-02-24
Volume
117
Issue
8
Pages
2396-2404
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2010476996
Cited by
75
References
4
FWCI
4.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. https://app.cochat.ai/papers/10.1182/blood-2010-04-278788
The paper
Annunziata, C. M., Hernandez, L., Davis, R. E., Zingone, A., Lamy, L., Lam, L. T., Hurt, E. M., Shaffer, A. L., Kuehl, W. M., & Staudt, L. M. (2011). A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood. https://doi.org/10.1182/blood-2010-04-278788

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.